US Bancorp DE Raises Stock Position in AVANOS MEDICAL, INC. (NYSE:AVNS)

US Bancorp DE raised its stake in shares of AVANOS MEDICAL, INC. (NYSE:AVNS) by 7.7% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 15,184 shares of the company’s stock after purchasing an additional 1,091 shares during the quarter. US Bancorp DE’s holdings in AVANOS MEDICAL were worth $218,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of AVNS. T. Rowe Price Investment Management Inc. boosted its holdings in shares of AVANOS MEDICAL by 27.2% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,011,312 shares of the company’s stock valued at $47,941,000 after buying an additional 644,267 shares in the last quarter. Clark Estates Inc. NY purchased a new position in AVANOS MEDICAL in the 1st quarter worth about $7,077,000. Pacer Advisors Inc. purchased a new position in AVANOS MEDICAL in the 1st quarter worth about $6,056,000. Brown Advisory Inc. raised its position in AVANOS MEDICAL by 12.0% in the 4th quarter. Brown Advisory Inc. now owns 1,905,094 shares of the company’s stock worth $30,329,000 after buying an additional 204,218 shares during the last quarter. Finally, Diamond Hill Capital Management Inc. purchased a new stake in shares of AVANOS MEDICAL during the 1st quarter valued at about $2,800,000. Institutional investors own 95.17% of the company’s stock.

AVANOS MEDICAL Trading Up 1.9%

AVNS stock opened at $10.95 on Friday. AVANOS MEDICAL, INC. has a 1-year low of $9.30 and a 1-year high of $25.36. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.64 and a quick ratio of 1.58. The company has a market capitalization of $508.22 million, a price-to-earnings ratio of -1.09 and a beta of 1.12. The business has a 50 day simple moving average of $11.79 and a two-hundred day simple moving average of $13.26.

AVANOS MEDICAL (NYSE:AVNS) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.01). The business had revenue of $175.00 million during the quarter, compared to the consensus estimate of $165.50 million. AVANOS MEDICAL had a positive return on equity of 6.16% and a negative net margin of 66.89%. During the same quarter in the previous year, the company earned $0.34 earnings per share. Research analysts anticipate that AVANOS MEDICAL, INC. will post 1.32 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, Wall Street Zen lowered shares of AVANOS MEDICAL from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 9th.

About AVANOS MEDICAL

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.